THIS PAGE IS UNDER CONSTRUCTION
On November 13, 2017, the United States Food and Drug Administration (FDA) has approved Abilify MyCite, a pill which can digitally track whether the patients have taken their medication or not.
Abilify MyCite (aripiprazole with sensor) consists of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. When the tablet containing the drug and the sensor is swallowed and comes in contact with the stomach fluids, the sensor is activated and can send that information as a signal to wearable patch.
The patch can then transmit that information to an app on a smartphone which enables patients to keep track of ingested medication. The patients can also authorize and share with their caregivers or physicians (via a web-based portal), data showing the date and time that they took the pills.
The pill is a collaboration between Otsuka pharmaceuticals, the manufacturer of Abilify and Proteus Digital Health, the company that created the sensor used in the pill.
Abilify MyCite is FDA-approved for the same indications as Abilify is, i.e, treatment of schizophrenia, acute treatment of manic and mixed episode with bipolar I disorder and for adjunctive treatment of major depressive disorder in adults.
Related Pages
References
Abilify MyCite Prescribing Information
Food and Drug Administration (FDA) announcement
Peters-Strickland T, Pestreich L, Hatch A, Rohatagi S, Baker RA, Docherty JP, Markovtsova L, Raja P, Weiden PJ, Walling DP. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatr Dis Treat. 2016 Oct 11;12:2587-2594. eCollection 2016. PubMed PMID: 27785036; PubMed Central PMCID: PMC5067053.
Copyright © 2017, Simple and Practical Mental Health. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.